ArticleBioarchitecture2016
Using both strands: The fundamental nature of antisense transcription.
Article in Bioarchitecture, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Nucleotide resolution 4-thiouridine sequencing by SNU-Seq and sf4sU-Seq reveals the transcriptional responsiveness of an epigenetically primed human genome.Nucleic acids research · 2026Article
- Paradigm Lost.Cancers · 2025Article
- Size fractionated NET-Seq reveals a conserved architecture of transcription units around yeast genes.Yeast (Chichester, England) · 2024Article
- Navigating the Multiverse of Antisense RNAs: The Transcription- and RNA-Dependent Dimension.Non-coding RNA · 2022Review
- Antisense non-coding transcription represses the PHO5 model gene at the level of promoter chromatin structure.PLoS genetics · 2022Article
- Article
- There and Back Again: Hox Clusters Use Both DNA Strands.Journal of developmental biology · 2021Review
- Continuous transcription initiation guarantees robust repair of all transcribed genes and regulatory regions.Nature communications · 2020Article
- Long Non-coding RNAs in Myeloid Malignancies.Frontiers in oncology · 2019Review
- Antisense transcription-dependent chromatin signature modulates sense transcript dynamics.Molecular systems biology · 2018Article
- Antisense transcription repressesEMBO reports · 2017Article
- Developmental transitions in Arabidopsis are regulated by antisense RNAs resulting from bidirectionally transcribed genes.RNA biology · 2017Article
- Termination factor Rho: From the control of pervasive transcription to cell fate determination in Bacillus subtilis.PLoS genetics · 2017Article
- Paf1 Has Distinct Roles in Transcription Elongation and Differential Transcript Fate.Molecular cell · 2017Article
Corrections and comments
- Comment on
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-coding transcription across the antisense strands of genes is an abundant, pervasive process in eukaryotes from yeast to humans, however its biological function remains elusive. Here, we provide commentary on a recent study of ours, which demonstrates a genome-wide role for antisense transcription: establishing a unique, dynamic chromatin architecture over genes. Antisense transcription increases the level of nucleosome occupancy and histone acetylation at the promoter and body of genes, without necessarily modulating the level of protein-coding sense transcription. It is also associated with high levels of histone turnover. By allowing genes to sample a wider range of chromatin configurations, antisense transcription could serve to make genes more sensitive to changing signals, priming them for responses to developmental programs or stressful cellular environments. Given the abundance of antisense transcription and the breadth of these chromatin changes, we propose that antisense transcription represents a fundamental, canonical feature of eukaryotic genes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.